Processa Pharmaceuticals, Inc. PCSA
1.56 USD -0.13 (-7.69%)
Regular-session close
1.55 -0.01 -0.64%
After hours · Nov 20, 4:00 PM ET
1.39 Day range 1.66
1.04 52-week range 8.88
- YTD
- -45.83%
- 1 year
- -77.13%
Benzinga news
benzinga.com Processa Pharmaceuticals Appoints Gregory J. Flesher Operations Chief Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory
benzinga.com Processa Pharmaceuticals Announces FDA Clears Its Investigational New Drug Application For Phase 2 Trial Of VT-7208 In Chronic Spontaneous Urticaria Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
